Klotho Neurosciences, Inc. Cash Flow Conversion Efficiency
Klotho Neurosciences, Inc. cash flow conversion efficiency. Based on the latest financial reports, Klotho Neurosciences, Inc. (KLTO) has a cash flow conversion efficiency ratio of -0.110x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.09 Million) by net assets ($9.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Klotho Neurosciences, Inc. (2021–2024)
Cash flow conversion efficiency of Klotho Neurosciences, Inc. from 2021 to 2024. This chart illustrates how Klotho Neurosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View KLTO live share price for real-time trading data and today's change.
Klotho Neurosciences, Inc. Cash Flow Conversion Ratio Explained
Klotho Neurosciences, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Klotho Neurosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Klotho Neurosciences, Inc. ranked by their cash flow conversion efficiency. Also see how much is Klotho Neurosciences, Inc. worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
York Timber Holdings Ltd
JSE:YRK
|
0.024x |
|
FoundPac Group Bhd
KLSE:5277
|
0.072x |
|
Aeon Motor Co Ltd
TWO:1599
|
0.074x |
|
De Poan Pneumatic
TWO:1570
|
0.024x |
|
EgnsINVEST Ejendomme Tyskland A/S
CO:EGNETY
|
0.003x |
|
Lix Solution Co.Ltd
KQ:029480
|
0.004x |
|
Balfour Beatty plc
LSE:BBY
|
0.200x |
|
Orad-M
TA:ORAD
|
0.098x |
Annual Cash Flow Conversion Efficiency for Klotho Neurosciences, Inc. (2021–2024)
The table below shows the annual cash flow conversion efficiency of Klotho Neurosciences, Inc. from 2021 to 2024. Review KLTO FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.19 Million | $-2.95 Million | -2.486x | -217.99% |
| 2023-12-31 | $571.72K | $-446.92K | -0.782x | -53.74% |
| 2022-12-31 | $1.18 Million | $-599.57K | -0.508x | -83.75% |
| 2021-12-31 | $1.03 Million | $-284.02K | -0.277x | -- |
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed it… Read more